PROTIVOOPUKhOLEVYY EFFEKT ANALOGOV SOMATOSTATINA PRI SOMATOTROPINOMAKh: OBZOR POSLEDNIKh ISSLEDOVANIY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review is dedicated to the issues of classification, diagnosis, clinical course and methods of treatment of somatotroph pituitary adenomas. The mechanisms of the antiproliferative effect of somatostatin analogues and their potential use in the presence of absolute or relative contraindications to surgery are discussed. The results of a meta-analysis and clinical studies confirming not only antisecretory, but the antitumor effects of somatostatin analogues are presented.

全文:

受限制的访问

参考

  1. Korczak A., Renner U., Karl Stalla G. Advances in understanding pituitary tumors. Prime Rep. 2014; 2(6): 5.
  2. Katznelson L., Atkinson J.L.D., Cook D.M., et al. American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine practice. 2011; 17(4): 1-44.
  3. Пронин В.С., Потешкин Ю.Е., Гитель Е.П. и др. Современная стратегия диагностики и лечения соматотропином. М., 2013. 192 с.
  4. Kontogeorgos G. Classification and Pathology of PituitaryTumors. Endocrine.2005; 28(1): 27-35.
  5. Pawlikowski M., Kunert-Radek J., Radek M. Plurihormonality of pituitary adenomas in light of immunohistochemical studies. Endokrynologia Polska. 2010; 61(1): 63-6.
  6. Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2009; 12(3): 256-60.
  7. Kontogeorgos G. Predictive Markers of Pituitary Adenoma Behavior. Neuroendocrinology. 2006; 83: 179-88.
  8. Knosp E. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery.1989; 25: 927-30.
  9. Jaffrain-Rea M.L. Di Stefano D., Minniti G., et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting. Endocrine-Related Cancer. 2002; 9: 103-13.
  10. Thapar K., Kovacs K.T., Stefaneanu L., et al. Antiproliferative effect of the somatostatin analogue treatment on growth hormone-producing pituitary tumors: results of multicenter randomized trial. Mayo Clin. Proc.1997; 72: 893-90.
  11. Bronstein M.D. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm. Res. 2006; 35: 129-34.
  12. Turner H.E., Nagy Z., Gatter K.C., et al. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J. Endocr. 2000; 165: 475-81.
  13. Wang M., Mou C., Jiang M. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur. J. Endocrinol 2012; 166(5): 797-802.
  14. Melmed S., Colao A., Barkan A., et al. Guidelines for acromegaly management: an update. J. Clin.Endocrinol. Metab. 2009; 94: 1509-17.
  15. Krzentowska-Korek A., Golkowski F., Baldys-Waligorska A., et al. Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary. 2011; 14(2): 157-62.
  16. Karavitaki N., Turner H.E., Adams C.B., et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin. Endocrinol. (Oxf). 2008; 68: 970-75.
  17. Petersenn S., Buchfelder M., Reincke M., et al. Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. Eur. J. Endocrinol. 2008; 159(5): 525-32.
  18. Kaltsas G.A., Isidori A.M., Florakis D., et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J. Clin. Endocrinol. Metab. 2001; 86: 1645-52.
  19. Barkan A.L. Radiotherapy in acromegaly: the argument against. Clin. Endocrinol. 2003; 58: 132-35.
  20. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol. Ther. 2004; 102: 61-85.
  21. Takei M. Suzuki M, Kajiva H., et al. Immunohistochemical detection of Somatostatin Receptor (SSTR) Subtypes 2A and 5 in Pituitary Adenoma from Acromegalic Patients: Good Correlation with Preoperative Response to Octreotide. Endocrin. Pathol. 2007; 18(4): 208-16.
  22. Ezzat S., Kontogeorgos G., Redelmeier D.A., et al. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur. J. Endocrinol. 1995; 133: 686-90.
  23. Fougner S.L., Bogota O.C., Berg J.P., et al. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin. Endocrinol. (Oxf). 2008; 68: 458-65.
  24. Chalabi M., Duluc C., Caron P., et al. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends Endocrinol. Metab. 2014; 25(3): 115-27.
  25. Zatelli M.C., Ambrosio M.R., Bondanelli E.M., Uberti C. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur. J. Endocrinol. 2007; 156(Suppl 1): S29-35.
  26. Carlsen S., Lund-Johansen M., Schreiner T., et al. Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure ShortTerm Postoperative Rates: A Prospective, Randomized Trial. J. Clin. Endocrinol. Metab. 2008; 93(8): 2984-90.
  27. Florio, T., Thellung S., Corsaro A, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin. Endocrinol. (Oxf). 2003; 59(1): 115-28.
  28. Freda P.U., Katznelson L., van der Lely A.J., et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 2005; 90: : 4465-73.
  29. Bevan J.S. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 2005; 90(3): 1856-63.
  30. Анциферов М.Б., Пронин В.С., Алексеева Т.М. Медикаментозное лечение пациентов с акромегалией, частично резистентных к терапии аналогами соматостатина. Фарматека. 2011; 16: 49-55.
  31. Giustina A., Mazziotti G., Torri V., et al. Metaanalysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012; 7(5)
  32. Caron P.J., Bevan J.S., Petersenn S., et al. Tumor Shrinkage with Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial. J. Clin. Endocrinol. Metab. 2013.
  33. Bevan J.S., Newell-Price J., Wass J.A., et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin. Endocrinol. (Oxf). 2008; 68(3): 343-49.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##